imatinib mesylate has been researched along with Pulmonary Hypertension in 88 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (23.86) | 29.6817 |
| 2010's | 63 (71.59) | 24.3611 |
| 2020's | 4 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Carter, LL; Clemons, B; Douthitt, A; Galkin, A; Gandjeva, A; Garcia, E; Guimond, D; Kennedy, M; Osterhout, R; Salter-Cid, L; Sitapara, R; Slee, D; Tuder, RM; Zisman, LS | 1 |
| Akaki, K; Asano, R; Hia, F; Inagaki, T; Ishibashi, T; Ishibashi-Ueda, H; Manabe, Y; Masaki, T; Mino, T; Mori, H; Morinobu, A; Morita, S; Nakaoka, Y; Nakatsuka, Y; Ogo, T; Okazawa, M; Sato, A; Takeuchi, O; Tsujimura, T; Uehata, T; Vandenbon, A; Yaku, A; Yoshinaga, M | 1 |
| Fujioka, M; Hara, T; Hirata, KI; Suzuki, M; Taniguchi, Y; Yoshikawa, S | 1 |
| Jeong, JO; Jo, DY; Lee, HJ; Lee, MW; Park, JH; Ryu, H; Song, IC; Sun, BJ; Yeon, SH; Yun, HJ | 1 |
| Akashi, K; Aoki, K; Aoki, T; Arita, T; Iwasaki, H; Kamimura, T; Kato, K; Matsushima, T; Minami, M; Miyamoto, T; Muta, T; Ogawa, R; Takenaka, K; Tanimoto, K; Yamasaki, S | 1 |
| Jasińska-Stroschein, M; Orszulak-Michalak, D; Oszajca, K; Ruchwa, J; Świtlik, W | 1 |
| Imai, Y; Kario, K; Kubota, K; Shinozaki, T | 1 |
| Matsubara, H; Miyaji, K; Ogawa, A | 1 |
| Higuchi, M; Hikasa, Y; Leong, ZP; Okida, A; Yamano, Y | 1 |
| Barst, RJ; Bourge, RC; Feldman, J; Frost, AE; Galié, N; Ghofrani, HA; Gómez-Sánchez, MA; Grimminger, F; Grünig, E; Hassoun, PM; Hoeper, MM; Lawrence, D; Morrell, NW; Peacock, AJ; Quinn, DA; Satoh, T; Simonneau, G; Tapson, VF; Torres, F | 1 |
| Abid, S; Adnot, S; Amsellem, V; Dubois-Randé, JL; Houssaini, A; Marcos, E; Mouraret, N; Rideau, D; Saker, M; Tissot, CM; Wan, F | 1 |
| Humbert, M | 1 |
| Bendjelloul, F; Courtman, DW; Deng, Y; Ormiston, ML; Parker, TG; Rundle, N; Stewart, DJ; Tsoporis, JN | 1 |
| Mucke, H | 1 |
| Aboagye, EO; Ashek, A; Barnes, G; Cotroneo, E; Cupitt, J; Dabral, S; Dubois, O; El-Bahrawy, MA; Fang, W; Gibbs, JS; Gsell, W; He, JG; Howard, LS; Jones, H; Nguyen, QD; Pullamsetti, SS; Tomasi, G; Wang, L; Wilkins, MR; Zhao, L | 1 |
| Baber, S; Kadowitz, PJ; Lasker, GF; Lasky, JA; Pankey, EA; Thammasiboon, S | 1 |
| Arita, N; Arita, S; Hikasa, Y | 1 |
| Bergot, E; Godinas, L; Guignabert, C; Humbert, M; Montani, D; Perros, F; Seferian, A; Sibille, Y | 1 |
| Fancher, KM; Green, MR; Newton, MD | 1 |
| Abe, K; Alvarez, D; Alzoubi, A; Järvinen, TA; Komatsu, M; Mann, D; McMurtry, IF; O'Neill, K; Oka, M; Ruoslahti, E; Toba, M; Urakami, T | 1 |
| Barst, RJ; Campbell, P; Peacock, A; Quinn, D; Rocha, GQ; Shah, AM; Solomon, SD | 1 |
| Adachi, S; Hirashiki, A; Kondo, T; Matsubara, H; Miyaji, K; Murohara, T; Nakaguro, M; Ogawa, A; Yokoi, T | 1 |
| Jasińska-Stroschein, M; Orszulak-Michalak, D; Owczarek, J; Plichta, P | 1 |
| Akagi, S; Ito, H; Matsubara, H; Nakamura, K; Ogawa, A; Sarashina, T | 1 |
| Barberà, JA | 1 |
| Al-Naamani, N; Hill, NS; Preston, IR; Roberts, KE | 1 |
| Bálint, Z; Dahal, BK; Kwapiszewska, G; Murmann, K; Schermuly, RT; Seeger, W; Veith, C; Weissmann, N; Wygrecka, M; Zakrzewicz, D | 1 |
| Hohenforst-Schmidt, W; Huang, H; Kakolyris, S; Kioumis, I; Lampaki, S; Li, Q; Organtzis, J; Papaiwannou, A; Petridis, D; Pitsiou, G; Porpodis, K; Syrigos, K; Tsiouda, T; Turner, JF; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Campbell, P; Claggett, B; Querejeta Roca, G; Quinn, D; Shah, AM; Solomon, SD; Vazir, A | 1 |
| Abe, H; Araki, K; Fujino, T; Fukada, I; Hatano, M; Ito, Y; Iwase, T; Minatsuki, S; Numakura, S; Ushiku, T | 1 |
| Behr, J; Borst, MM; Ewert, R; Ghofrani, HA; Grünig, E; Halank, M; Hoeper, MM; Klose, H; Lange, TJ; Olschewski, H; Opitz, C; Rosenkranz, S; Seeger, W; Speich, R; Ulrich, S; Welte, T; Wilkens, H | 1 |
| Jasińska-Stroschein, M; Kącikowska, J; Orszulak-Michalak, D; Owczarek, J; Surowiecka, A | 1 |
| Bouillon, T; Flesch, G; Quinn, D; Renard, D; Zhou, P | 1 |
| Abe, H; Fukayama, M; Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Komuro, I; Maki, H; Minatsuki, S; Miura, I; Muraoka, H; Nagai, R; Tanaka, M; Yao, A; Yao, T | 1 |
| Lüscher, TF | 1 |
| Alavian, KN; Ashek, A; Bozorgi, S; Busbridge, M; Cotroneo, E; Dubois, O; Wang, L; Wharton, J; Wilkins, MR; Zhao, L | 1 |
| Akagi, S; Egashira, K; Ito, H; Matoba, T; Matsubara, H; Miura, D; Nakamura, K; Ogawa, A; Saito, Y | 1 |
| Breitenstein, A; Domenighetti, G; Fischler, M; Huber, LC; Speich, R; Treder, U; Ulrich, S | 1 |
| Olschewski, H | 1 |
| Jiang, X; Jing, ZC; Sun, K; Wu, DC; Zhang, HD; Zhang, R | 1 |
| Barst, RJ; Chang, HJ; Dario Vizza, C; Felser, JM; Frantz, RP; Frost, AE; Fukumoto, Y; Galié, N; Ghofrani, HA; Hassoun, PM; Hoeper, MM; Klose, H; Lawrence, D; Matsubara, H; Morrell, NW; Peacock, AJ; Pfeifer, M; Quinn, DA; Simonneau, G; Tapson, VF; Torres, F; Yang, W | 1 |
| Knock, GA | 1 |
| Cicha, K; Jasińska-Stroschein, M; Orszulak-Michalak, D; Owczarek, J | 1 |
| Campbell, P; Claggett, B; Querejeta Roca, G; Shah, AM; Solomon, SD | 1 |
| Liu, Y; Ma, C; Shen, T; Song, S; Yi, Z; Yu, L; Yu, X; Zhang, C; Zhang, H; Zhang, M; Zheng, X; Zhu, D | 1 |
| Bouchet, S; Chaumais, MC; Guignabert, C; Huertas, A; Humbert, M; Jutant, EM; Le Hiress, M; Manéglier, B; Molimard, M; Montani, D; Phan, C; Rousselot, P; Sattler, C; Seferian, A; Simonneau, G; Sitbon, O; Tamura, Y; Thuillet, R; Tu, L | 1 |
| Baumgart, B; Bunch, RT; Graziano, M; Guha, M; Hennan, J; Li, J; Sanderson, T; Simic, D; Wallis, N; Woicke, J | 1 |
| Boonstra, A; Overbeek, MJ; Smit, EF; van Nieuw Amerongen, GP; Vonk-Noordegraaf, A | 1 |
| Broomé, M; Frenckner, B; Lindström, M; Radell, P | 1 |
| Busch, AE; Dony, E; Ellinghaus, P; Ghofrani, HA; Grimminger, F; Klein, M; Milting, H; Nikolova, S; Pullamsetti, SS; Riedl, B; Savai, R; Schäfer, S; Schermuly, RT; Weissmann, N | 1 |
| Castillo Palma, MJ; García Hernández, FJ; Garrido Rasco, R; González León, R; Ocaña Medina, C; Sánchez Román, J | 1 |
| Bovenschulte, H; Dumitrescu, D; Erdmann, E; Rosenkranz, S; ten Freyhaus, H | 1 |
| Csete, M; Heffron, T; Knowles, D; Lawrence, EC; Tapper, EB | 1 |
| Chhina, MK; Grant, GM; Nargues, W; Nathan, SD | 1 |
| Grimminger, F; Schermuly, RT | 1 |
| Saito, K; Sawamukai, N; Shimajiri, S; Tanaka, Y; Yamaoka, K; Yukawa, S | 1 |
| Barst, RJ; Ghofrani, HA; Golpon, H; Grimminger, F; Hoeper, MM; Morrell, NW; Olschewski, H; Pascoe, S; Peacock, AJ; Shapiro, S; Toshner, M | 1 |
| Hatano, M; Hirata, Y; Kinugawa, K; Nagai, R; Shiga, T; Yao, A | 1 |
| Cohen-Kaminsky, S; Gambaryan, N; Humbert, M; Mazmanian, GM; Montani, D; Perros, F | 1 |
| Akagi, S; Fuke, S; Ito, H; Kohno, K; Kusano, KF; Matsubara, H; Miura, A; Miura, D; Morita, H; Nagase, S; Nakamura, K; Nishii, N; Ogawa, A; Ohe, T; Oto, T; Otsuka, F; Yamanaka, R; Yutani, C | 1 |
| Abe, K; Alzoubi, A; Fagan, KA; Gairhe, S; Gerthoffer, WT; Ito, M; Koubsky, K; McMurtry, IF; Oka, M; Ota, H; Toba, M | 1 |
| Abouzahir, A; Amezyane, T; Badaoui, M; El Khattabi, A; Elomri, N; Elqatni, M; Fatihi, J; Ghafir, D; Hammi, S; Jira, M; Mekouar, F; Sekkach, Y; Smaali, J | 1 |
| Berghausen, E; Caglayan, E; Dumitrescu, D; Rosenkranz, S; ten Freyhaus, H; Vantler, M | 1 |
| Mathew, R | 1 |
| Bergeron, A; Bergot, E; Bourdin, A; Bouvaist, H; Canuet, M; Girerd, B; Guignabert, C; Günther, S; Humbert, M; Jaïs, X; Macro, M; Montani, D; Natali, D; O'Callaghan, DS; Perros, F; Pison, C; Poubeau, P; Savale, L; Simonneau, G; Sitbon, O; Tubert-Bitter, P; Zalcman, G | 1 |
| Dahal, BK; Ghofrani, HA; Kojonazarov, B; Kwapiszewska, G; Markart, P; Marsh, LM; Meinhardt, A; Olschewski, A; Preissner, KT; Schermuly, RT; Seeger, W; Steinhoff, M; Taube, C; Weissmann, N; Wygrecka, M | 1 |
| Berghausen, EM; Brandes, RP; Butrous, E; Butrous, G; Dabral, S; Dahal, BK; Ghofrani, HA; Grimminger, F; Pullamsetti, SS; Rosenkranz, S; Savai, R; Schermuly, RT; Seeger, W; Tretyn, A; Weissmann, N | 1 |
| Chaumais, MC; De Man, FS; Dorfmüller, P; Eddahibi, S; Fadel, E; François, C; Girerd, B; Guignabert, C; Huertas, A; Humbert, M; Lecerf, F; Montani, D; Perros, F; Tu, L | 1 |
| Kovacs, G; Olschewski, H | 1 |
| Beach, S; Bonneau, O; Burton, V; Ciuclan, L; Clay, I; Duggan, N; Fox, R; Good, R; Hussey, MJ; Jarai, G; Jones, P; Konstantinova, I; MacLean, MR; Pearce, A; Rowlands, DJ; Thomas, M; Westwick, J | 1 |
| Bossone, E; D'Amore, C; Dellegrottaglie, S; Gargiulo, P; Leosco, D; Losco, T; Marciano, C; Musella, F; Perrone-Filardi, P; Rengo, G; Savarese, G | 1 |
| Morrell, N; Sitbon, O | 1 |
| Kosanovic, D; Schermuly, R | 1 |
| Ghofrani, HA; Grimminger, F; Seeger, W | 1 |
| Barst, RJ | 1 |
| Dony, E; Ghofrani, HA; Grimminger, F; Lai, YJ; Pullamsetti, S; Roth, M; Savai, R; Schermuly, RT; Seeger, W; Sydykov, A; Weissmann, N | 1 |
| Hong-eng, S; Limsuwan, A; Pakakasama, S; Rochanawutanon, M | 1 |
| Ghofrani, HA; Grimminger, F; Schermuly, RT; Seeger, W; Weissmann, N | 1 |
| Archer, SL; Michelakis, ED | 1 |
| Ahmadi, T; Farber, HW; Patterson, KC; Weissmann, A | 1 |
| Humbert, M; Parent, F; Simonneau, G; Sitbon, O; Souza, R | 1 |
| Di Stefano, F | 1 |
| Ghofrani, HA; Grimminger, F; Rosenkranz, S | 1 |
| Gaine, SP; O'Callaghan, D; O'Callaghan, DS | 1 |
| Semeniuk, GB | 1 |
| Fairman, P; Grinnan, DC; Pinson, J | 1 |
| Binder, T; Jäger, U; Krauth, MT; Ohler, L; Valent, P | 1 |
| Dorfmüller, P; Durand-Gasselin, I; Eddahibi, S; Emilie, D; Fadel, E; Hervé, P; Humbert, M; Le Pavec, J; Mazmanian, M; Mercier, O; Montani, D; Mussot, S; Perros, F; Simonneau, G; Souza, R; Tcherakian, C | 1 |
16 review(s) available for imatinib mesylate and Pulmonary Hypertension
| Article | Year |
|---|---|
The role of imatinib in the treatment of pulmonary hypertension.
Topics: Animals; Benzamides; Clinical Trials as Topic; Disease Progression; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2013 |
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Fibroblasts; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Niacinamide; Phenylurea Compounds; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pulmonary Circulation; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sorafenib; src-Family Kinases; Thiazoles; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant | 2016 |
[Treatment with imatinib for refractory PAH].
Topics: Animals; Apoptosis; Becaplermin; Benzamides; Cell Proliferation; Clinical Trials as Topic; Female; Gene Expression; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pulmonary Artery; Pulmonary Veno-Occlusive Disease; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Vasoconstriction | 2014 |
[Imatinib for pulmonary arterial hypertension].
Topics: Benzamides; Germany; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Off-Label Use; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Survival Rate; Ventricular Dysfunction, Right | 2014 |
Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis.
Topics: Administration, Oral; Antihypertensive Agents; Benzamides; Endothelin Receptor Antagonists; Exercise Test; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Phosphodiesterase 5 Inhibitors; Piperazines; Prostaglandins; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Treatment Outcome; Vasodilator Agents | 2015 |
Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Vasodilation | 2010 |
PDGF receptor and its antagonists: role in treatment of PAH.
Topics: Animals; Benzamides; Clinical Trials as Topic; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Vascular Diseases | 2010 |
Involvement of mast cells in systemic sclerosis.
Topics: Adaptive Immunity; Animals; Arthritis, Rheumatoid; Benzamides; Disease Models, Animal; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Immunity, Innate; Male; Mast Cells; Mice; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic | 2010 |
Imatinib mesylate for the treatment of pulmonary arterial hypertension.
Topics: Animals; Benzamides; Clinical Trials as Topic; Drug Delivery Systems; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Time Factors; Treatment Outcome | 2012 |
Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension.
Topics: Benzamides; Endothelin Receptor Antagonists; Epoprostenol; Exercise; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Hemodynamics; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Phosphodiesterase 5 Inhibitors; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Regression Analysis; Treatment Outcome; Walking | 2013 |
Pathways in pulmonary arterial hypertension: the future is here.
Topics: Acetamides; Animals; Antihypertensive Agents; Benzamides; Clinical Trials as Topic; Drugs, Investigational; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Epoprostenol; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lisuride; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Serotonin Antagonists; Sulfonamides | 2012 |
PDGF signaling in pulmonary arterial hypertension.
Topics: Animals; Benzamides; Disease Models, Animal; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pulmonary Artery; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2005 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Calcium Channel Blockers; Comorbidity; Dichloroacetic Acid; Drug Therapy, Combination; Epoprostenol; Evidence-Based Medicine; Fluoxetine; Humans; Hypertension, Pulmonary; Iloprost; Imatinib Mesylate; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins, Synthetic; Pulmonary Artery; Purines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Simvastatin; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2006 |
[Future aspects of the treatment of pulmonary arterial hypertension].
Topics: Animals; Benzamides; Drug Therapy; Enzyme Activators; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Vasodilator Agents | 2006 |
Combination therapy and new types of agents for pulmonary arterial hypertension.
Topics: Adrenomedullin; Angiopoietin-1; Antihypertensive Agents; Benzamides; Bosentan; Drug Therapy, Combination; Eicosanoids; Epoprostenol; Genetic Therapy; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Piperazines; Platelet Aggregation Inhibitors; Prostaglandins; Protein Serine-Threonine Kinases; Purines; Pyrimidines; rho-Associated Kinases; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sildenafil Citrate; Sulfonamides; Sulfones; Vasoactive Intestinal Peptide; Vasodilator Agents | 2007 |
10 trial(s) available for imatinib mesylate and Pulmonary Hypertension
| Article | Year |
|---|---|
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
Topics: Adolescent; Adult; Aged; Benzamides; Double-Blind Method; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Hematoma, Subdural; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2013 |
Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.
Topics: Adult; Aged; Animals; Benzamides; Cell Division; Dichloroacetic Acid; Disease Models, Animal; Drug Monitoring; Familial Primary Pulmonary Hypertension; Female; Fibroblasts; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression Profiling; Glycolysis; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Indoles; Lung; Male; Middle Aged; Monocrotaline; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Sunitinib; Young Adult | 2013 |
Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension.
Topics: Analysis of Variance; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Echocardiography, Doppler; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Hypertrophy, Left Ventricular; Imatinib Mesylate; Male; Middle Aged; Observer Variation; Stroke Volume; Tricuspid Valve Insufficiency; Vascular Resistance; Ventricular Dysfunction, Right | 2015 |
Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension.
Topics: Adult; Benzamides; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Ultrasonography; Vascular Resistance; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right | 2015 |
Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Bosentan; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Sildenafil Citrate; Sulfonamides; Vascular Resistance; Young Adult | 2015 |
Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Tolerance; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2015 |
Right Atrial Function in Pulmonary Arterial Hypertension.
Topics: Age Factors; Atrial Function, Right; Cardiac Catheterization; Case-Control Studies; Echocardiography; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sex Factors; Vascular Resistance | 2015 |
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Dasatinib; E-Selectin; Female; Genetic Predisposition to Disease; Hemodynamics; Humans; Hypertension, Pulmonary; Hypoxia; Imatinib Mesylate; Intercellular Adhesion Molecule-1; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Male; Middle Aged; Mitochondria; Rats; Reactive Oxygen Species; Vascular Cell Adhesion Molecule-1 | 2016 |
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.
Topics: Adult; Benzamides; Double-Blind Method; Exercise Test; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Intention to Treat Analysis; Lung; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Respiratory Function Tests; Treatment Outcome | 2010 |
Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension.
Topics: Aged; Becaplermin; Benzamides; Cardiac Output; Cohort Studies; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Middle Aged; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Treatment Outcome; Vascular Resistance; Young Adult | 2010 |
62 other study(ies) available for imatinib mesylate and Pulmonary Hypertension
| Article | Year |
|---|---|
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.
Topics: Animals; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Hypoxia; Imatinib Mesylate; MicroRNAs; Monocrotaline; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats | 2022 |
Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages.
Topics: Animals; Biomarkers; Cytokines; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Imatinib Mesylate; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Interleukin-6; Leukocytes, Mononuclear; Macrophages, Alveolar; Mice; Platelet-Derived Growth Factor; Pulmonary Arterial Hypertension; Pulmonary Artery; Ribonucleases; RNA Stability; Vascular Remodeling | 2022 |
Imatinib Dramatically Improved Pulmonary Hypertension Caused by Pulmonary Tumor Thrombotic Microangiopathy (PTTM) Associated with Metastatic Breast Cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Thrombotic Microangiopathies | 2020 |
Pulmonary hypertension in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Echocardiography; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Young Adult | 2021 |
Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Dasatinib; Echocardiography; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pyrimidines; Treatment Outcome; Tricuspid Valve Insufficiency; Young Adult | 2017 |
Treatment with platelet-derived growth factor (PDGF) and rock inhibitors is related to declined nerve growth factor (NGF) signaling in an experimental model of rat pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Imatinib Mesylate; Male; Monocrotaline; Nerve Growth Factor; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; rho-Associated Kinases; RNA, Messenger; Signal Transduction | 2017 |
Imatinib dramatically alleviates pulmonary tumour thrombotic microangiopathy induced by gastric cancer.
Topics: Carcinoma, Signet Ring Cell; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Rare Diseases; Receptors, Platelet-Derived Growth Factor; Stomach Neoplasms; Thrombotic Microangiopathies; Tomography, X-Ray Computed | 2017 |
Efficacy and safety of long-term imatinib therapy for patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis.
Topics: Adult; Exercise Tolerance; Hemangioma, Capillary; Hemodynamics; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Kaplan-Meier Estimate; Lung Neoplasms; Lung Transplantation; Male; Middle Aged; Natriuretic Peptide, Brain; Protein Kinase Inhibitors; Pulmonary Veno-Occlusive Disease; Severity of Illness Index; Survival Rate; Treatment Outcome; Walk Test; Young Adult | 2017 |
Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imatinib Mesylate; Indoles; Male; Monocrotaline; Nestin; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pulmonary Artery; Pyrroles; Rats, Wistar; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2018 |
Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.
Topics: Animals; Apoptosis; Benzamides; Cell Proliferation; Cells, Cultured; Fluoxetine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hypertension, Pulmonary; Imatinib Mesylate; Male; Monocrotaline; Myocytes, Smooth Muscle; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pulmonary Artery; Pyrimidines; Rats; Rats, Wistar; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Impression, sunset.
Topics: Benzamides; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Piperazines; Pyrimidines | 2013 |
A lymphocyte-dependent mode of action for imatinib mesylate in experimental pulmonary hypertension.
Topics: Animals; Apoptosis; Benzamides; Cytokines; Disease Models, Animal; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imatinib Mesylate; Immunomodulation; Leukocyte Count; Lymphocyte Depletion; Lymphocytes; Male; Monocrotaline; Myocytes, Cardiac; Piperazines; Pyrimidines; Rats; Rats, Inbred F344; Rats, Nude | 2013 |
Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Benzamides; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imatinib Mesylate; Male; Monocrotaline; Muscle, Smooth, Vascular; Phosphodiesterase 4 Inhibitors; Piperazines; Potassium Channel Blockers; Protein Kinase Inhibitors; Pulmonary Artery; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor; Vasoconstriction; Vasodilation; Vasodilator Agents | 2013 |
Therapeutic effect of low-dose imatinib on pulmonary arterial hypertension in dogs.
Topics: Animals; Benzamides; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Female; Heart Failure; Hypertension, Pulmonary; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.
Topics: Administration, Sublingual; Amino Acid Sequence; Animals; Arterial Occlusive Diseases; Benzamides; Drug Delivery Systems; Familial Primary Pulmonary Hypertension; Hemodynamics; Hypertension, Pulmonary; Imatinib Mesylate; Infusions, Intravenous; Injections, Intravenous; Male; Molecular Sequence Data; Peptides; Piperazines; Pulmonary Artery; Pyrimidines; Rats; Rats, Sprague-Dawley; Treatment Outcome; Vasodilator Agents | 2014 |
Imatinib is partially effective for the treatment of pulmonary capillary hemangiomatosis.
Topics: Adult; Antihypertensive Agents; Antineoplastic Agents; Autopsy; Benzamides; Bosentan; Cardiac Catheterization; Dyspnea; Echocardiography; Epoprostenol; Fatal Outcome; Hemangioma, Capillary; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Lung Neoplasms; Male; Piperazines; Purines; Pyrimidines; Radiography, Thoracic; Sildenafil Citrate; Sulfonamides; Treatment Failure | 2014 |
Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Becaplermin; Benzamides; Disease Models, Animal; Drug Therapy, Combination; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imatinib Mesylate; Male; Monocrotaline; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Rats; Rats, Wistar; Receptors, Platelet-Derived Growth Factor; rho-Associated Kinases; Ventricular Pressure | 2014 |
Clinical research in pulmonary hypertension comes of age.
Topics: Benzamides; Biomarkers; Biomedical Research; Clinical Trials as Topic; Endothelin A Receptor Antagonists; Exercise Test; Hospitalization; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Multicenter Studies as Topic; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Sulfonamides; Walking | 2014 |
Imatinib as rescue therapy in a patient with pulmonary hypertension associated with Gaucher disease.
Topics: Adult; Benzamides; Female; Gaucher Disease; Hemodynamics; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Splenectomy; Time Factors; Treatment Outcome; World Health Organization | 2014 |
Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
Topics: Active Transport, Cell Nucleus; Animals; Antihypertensive Agents; Apoptosis; Becaplermin; Benzamides; Cell Adhesion; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Humans; Hypertension, Pulmonary; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Paxillin; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-sis; Pulmonary Artery; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Signal Transduction; Time Factors; Transfection; Tyrosine; Vascular Remodeling | 2014 |
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.
Topics: Administration, Inhalation; Benzamides; Erlotinib Hydrochloride; Gefitinib; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
Imatinib alleviated pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in a patient with metastatic breast cancer.
Topics: Breast Neoplasms; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Middle Aged; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Thrombotic Microangiopathies | 2015 |
HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension.
Topics: Animals; Drug Synergism; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imatinib Mesylate; Male; Monocrotaline; Organ Size; Rats; Rats, Wistar; Rosuvastatin Calcium; Simvastatin | 2015 |
Platelet-derived growth factor receptor-tyrosine kinase inhibitor, imatinib, is effective for treating pulmonary hypertension induced by pulmonary tumor thrombotic microangiopathy.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzamides; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung Neoplasms; Middle Aged; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stomach Neoplasms; Thrombotic Microangiopathies | 2015 |
Pulmonary embolism and pulmonary hypertension: two issues often neglected in cardiology.
Topics: Acetazolamide; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Oxygen; Peripheral Arterial Disease; Protein Kinase Inhibitors; Pulmonary Embolism; Randomized Controlled Trials as Topic; Thrombolytic Therapy | 2015 |
Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Benzamides; Cell Proliferation; Deficiency Diseases; Dichloroacetic Acid; Disease Models, Animal; Erythropoiesis; Ferric Compounds; Ferritins; Glycolysis; Hematinics; Homeostasis; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imatinib Mesylate; Iron; Iron Deficiencies; Liver; Male; Maltose; Piperazines; Pulmonary Artery; Pyrimidines; Rats, Sprague-Dawley; Signal Transduction; Time Factors; Transferrin; Vascular Remodeling | 2015 |
Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension.
Topics: Animals; Benzamides; Cells, Cultured; Disease Models, Animal; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Monocrotaline; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nanoparticles; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor | 2015 |
Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension.
Topics: Adult; Aged; Echocardiography; Female; Hematoma, Subdural; Hemodynamics; Humans; Hypertension, Pulmonary; Imatinib Mesylate; International Normalized Ratio; Longitudinal Studies; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Remission Induction; Severity of Illness Index; Treatment Outcome; Young Adult | 2015 |
Imatinib for Pulmonary Arterial Hypertension - Wonder Drug or Killer Drug?
Topics: Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Protein Kinase Inhibitors | 2015 |
Tyrosine kinases as key modulators of smooth muscle function in health and disease.
Topics: Animals; Dasatinib; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Rho Guanine Nucleotide Exchange Factors | 2015 |
Influence of imatinib at a low dose and sildenafil on pulmonary hypertension in rats.
Topics: Animals; Blood Pressure; Heart Rate; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Imatinib Mesylate; Male; Monocrotaline; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sildenafil Citrate; Vasodilator Agents | 2015 |
The role of PDGF-B/TGF-β1/neprilysin network in regulating endothelial-to-mesenchymal transition in pulmonary artery remodeling.
Topics: Animals; Cattle; Cell Hypoxia; Down-Regulation; Endothelial Cells; Endothelium; Hypertension, Pulmonary; Imatinib Mesylate; Immunoprecipitation; Mesoderm; Monocrotaline; Neprilysin; Proto-Oncogene Proteins c-sis; Pulmonary Artery; Rats; Signal Transduction; Transforming Growth Factor beta1; Vascular Remodeling | 2016 |
In vitro and in vivo evaluation of dasatinib and imatinib on physiological parameters of pulmonary arterial hypertension.
Topics: Animals; Antineoplastic Agents; Dasatinib; Endothelin-1; Gene Expression; Hemodynamics; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Male; Muscle Contraction; Muscle, Smooth, Vascular; Nitric Oxide; Protein Kinase Inhibitors; Pulmonary Artery; Pulmonary Circulation; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2017 |
Possible role of imatinib in clinical pulmonary veno-occlusive disease.
Topics: Benzamides; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Pulmonary Veno-Occlusive Disease; Pyrimidines; Vasodilator Agents | 2008 |
Platelet-derived growth factor inhibition--a new treatment of pulmonary hypertension in congenital diaphragmatic hernia?
Topics: Benzamides; Bosentan; Combined Modality Therapy; Continuous Positive Airway Pressure; Diuretics; Enteral Nutrition; Extracorporeal Membrane Oxygenation; Heart Failure; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Congenital; Humans; Hypertension, Pulmonary; Hypoxia; Iloprost; Imatinib Mesylate; Infant, Newborn; Male; Nitric Oxide; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sildenafil Citrate; Sulfonamides; Sulfones | 2008 |
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Topics: Animals; Benzamides; Benzenesulfonates; Blood Pressure; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Heart; Heart Ventricles; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Pulmonary Artery; Pyridines; Pyrimidines; raf Kinases; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Ventricular Remodeling | 2008 |
[Experience with imatinib to treat pulmonary arterial hypertension].
Topics: Adult; Benzamides; Chemical and Drug Induced Liver Injury; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Middle Aged; Piperazines; Platelet-Derived Growth Factor; Pyrimidines | 2008 |
Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.
Topics: Animals; Benzamides; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Systemic; Treatment Outcome; Ventricular Dysfunction, Right | 2009 |
Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Epoprostenol; Female; Humans; Hypertension, Portal; Hypertension, Pulmonary; Imatinib Mesylate; Liver Failure; Liver Transplantation; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Treatment Outcome | 2009 |
Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension.
Topics: Animals; Benzamides; Bone Marrow Cells; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Hypertension, Pulmonary; Hypoxia; Imatinib Mesylate; Male; Mice; Mice, Inbred C57BL; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2010 |
Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.
Topics: Adolescent; Adult; Apoptosis; Becaplermin; Benzamides; Cell Proliferation; Child; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Myocytes, Smooth Muscle; Piperazines; Proto-Oncogene Proteins c-sis; Pulmonary Artery; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.
Topics: Animals; Antihypertensive Agents; Benzamides; Benzenesulfonates; Blotting, Western; Calcium; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Pulmonary; Imatinib Mesylate; Male; Myosin Light Chains; Myosin-Light-Chain Phosphatase; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pulmonary Artery; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Sorafenib; Vasodilation; Vasodilator Agents; Ventricular Function, Left; Ventricular Function, Right; Ventricular Pressure | 2011 |
[Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].
Topics: Adult; Asthma; Benzamides; Electrocardiography; Eosinophils; Female; Humans; Hypereosinophilic Syndrome; Hypertension; Hypertension, Pulmonary; Imatinib Mesylate; Leukocyte Count; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protease Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2011 |
PDGF receptor blocker for pulmonary hypertension: a new agent in therapeutic arsenal.
Topics: Antihypertensive Agents; Benzamides; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2012 |
Pulmonary arterial hypertension in patients treated by dasatinib.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Bone Morphogenetic Protein Receptors, Type II; Calcium Channel Blockers; Dasatinib; Drug Utilization; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Hemodynamics; Humans; Hydroxyurea; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Registries; Thiazoles; Treatment Outcome | 2012 |
PAR-2 inhibition reverses experimental pulmonary hypertension.
Topics: Adolescent; Adult; Animals; Antibodies, Neutralizing; Becaplermin; Benzamides; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Ligands; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Monocrotaline; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oligopeptides; Piperazines; Proto-Oncogene Proteins c-sis; Pulmonary Artery; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, PAR-2; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Signal Transduction; Time Factors; Transfection; Tryptases; Young Adult | 2012 |
Role of Src tyrosine kinases in experimental pulmonary hypertension.
Topics: Animals; Apoptosis; Becaplermin; Benzamides; Cell Proliferation; Cells, Cultured; Chemotaxis; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Hemodynamics; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Imatinib Mesylate; Monocrotaline; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-sis; Pyrimidines; Rats; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Time Factors | 2012 |
A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.
Topics: Animals; Benzamides; Benzimidazoles; Case-Control Studies; Crk-Associated Substrate Protein; Disease Models, Animal; Endothelial Cells; Epidermal Growth Factor; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Gefitinib; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Mice; Monocrotaline; Myocytes, Smooth Muscle; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pulmonary Artery; Pyrimidines; Quinazolines; Quinolones; Rats; Signal Transduction | 2012 |
[Pulmonary hypertension].
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Benzamides; Drug Therapy, Combination; Early Medical Intervention; Epoprostenol; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Pyrazines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides | 2012 |
Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.
Topics: Animals; Benzamides; Disease Models, Animal; Hemodynamics; Hypertension, Pulmonary; Hypoxia; Imatinib Mesylate; Indoles; Mice; Mice, Knockout; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Serotonin; Tryptophan Hydroxylase | 2013 |
Are tyrosine kinase inhibitors the better serotonin inhibitors?
Topics: Animals; Benzamides; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tryptophan Hydroxylase | 2013 |
Imatinib for the treatment of pulmonary arterial hypertension.
Topics: Benzamides; Exercise Tolerance; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Vascular Resistance | 2005 |
Reversal of experimental pulmonary hypertension by PDGF inhibition.
Topics: Animals; Benzamides; Blood Pressure; Disease Models, Animal; Heart Ventricles; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Male; Mice; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pulmonary Artery; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor; Signal Transduction | 2005 |
Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Humans; Hyperplasia; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Vasodilator Agents | 2006 |
[Reverse remodeling -- paradigm shift in the treatment of pulmonary hypertension].
Topics: Benzamides; Cell Division; Drug Therapy, Combination; Endothelin-1; Endothelium, Vascular; Fibromuscular Dysplasia; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyrimidines; Vasodilator Agents | 2006 |
Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Heart Failure; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Middle Aged; Piperazines; Platelet-Derived Growth Factor; Pyrimidines | 2006 |
Long term imatinib treatment in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Pyrimidines | 2006 |
Pulmonary arterial hypertension and chronic myeloproliferative disorders.
Topics: Benzamides; Chronic Disease; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
[Pulmonary hypertension: tailored treatment].
Topics: Benzamides; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
Recurrence of severe pulmonary hypertension following the removal of a lung allograft.
Topics: Adult; Benzamides; Female; Graft Rejection; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung Transplantation; Piperazines; Pneumonectomy; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Ventilation-Perfusion Ratio | 2007 |
Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Heart Failure; Humans; Hypereosinophilic Syndrome; Hypertension, Pulmonary; Imatinib Mesylate; Male; Mitral Valve Insufficiency; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.
Topics: Apoptosis; Becaplermin; Benzamides; Cell Count; Cell Movement; Cell Proliferation; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Muscle, Smooth, Vascular; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pulmonary Artery; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; RNA, Messenger | 2008 |